VIDEO: Novel therapy shows clinical activity in EGFR-mutated NSCLC
Click Here to Manage Email Alerts
MADRID — A novel antibody-drug conjugate plus osimertinib showed clinical activity and a manageable safety profile in patients with relapsed/refractory, EGFR-mutated non-small cell lung cancer, according to a presentation at ESMO Congress.
Julia Rotow, MD, clinical director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, presented the initial safety and preliminary efficacy data from the first-in-human study of this antibody-drug conjugate — known as ABBV-637) — which consists of an EGFR–targeting antibody and B-cell lymphoma-extra large (BCL-XL) inhibitor, plus osimertinib (Tagrisso, AstraZeneca) for EGFR-mutated NSCLC.
“Notably, and of great interest, we know that prior small molecule B-cell XL inhibitor therapy has at times produced excess cytopenias or excess thrombocytopenia,” Rotow said, but high-grade thrombocytopenia or other cytopenia was uncommon in this study.
“Given this is an EGFR-antibody there was also interest in understanding whether we’d see excess EGFR-wildtype inhibition-related toxicities, like high-grade skin rash or diarrhea, and both of these were uncommon on this trial,” she told Healio. “This supports the potential feasibility of using a B-cell XL inhibitor delivered in a more specific ADC-directed fashion in this patient population.”
Collapse
Rotow J, et al. Abstract 1318MO. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.
Click Here to Manage Email Alerts